Lilly, Mubadala Bio announce landmark agreement to advance pharmaceutical contract manufacturing in Abu Dhabi (WAM - The Emirates News Agency) - Oct 21, 2026 - "This partnership will be supported from a 125,000 sqm site in KEZAD, Abu Dhabi, comprising packaging and warehousing facilities that further strengthen the company's pharmaceutical contract manufacturing, packaging and logistics capabilities and its ability to serve global industry partners from the UAE. Today's announcement builds on the UAE's leadership in advancing access to innovative medicines and strengthening personalised healthcare. On 3rd April 2026, the Emirates Drug Establishment (EDE) approved Foundayo (orforglipron) for chronic weight management, making the UAE the second country in the world to register the medicine."
Licensing / partnership • Obesity
|